| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.098 | 0.007 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.007 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.008 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.009 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.009 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.098 | 0.009 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.095 | 0.01 |